Gelonghui November 21丨Shanghai Kaibao (300039.SZ) said on the investor interactive platform that the company's leading product, Phlegm Heqing Injection, is an exclusively patented product and is a Class II new Chinese medicine in the country. In the prevention and control of “human avian influenza,” “influenza A (H1N1),” “influenza A (H1N1),” “influenza A (H7N9),” “hand, foot and mouth disease,” “dengue fever,” “Ebola,” and “Middle East respiratory syndrome,” “Ebola,” and “Middle East respiratory syndrome,” etc., it was classified by the National Health and Health Commission and the Administration of Traditional Chinese Medicine as a clinical guideline or treatment plan drug. In 2006, it was classified by the National Development and Reform Commission as a “reserve drug of traditional Chinese medicine for influenza prevention and treatment”, and has become a national strategic reserve drug.